We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Bioanalysis
BioTechniques
Future Drug Discovery
Future Medicinal Chemistry
Future Science OA
International Journal of Pharmacokinetics
Pharmaceutical Patent Analyst
Therapeutic Delivery
Review

Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles

    Mohammad Yahya Hanafi-Bojd

    Cellular & Molecular Research Center, Department of Pharmacology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

    Search for more papers by this author

    ,
    Legha Ansari

    School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    Search for more papers by this author

    &
    Bizhan Malaekeh-Nikouei

    *Author for correspondence:

    E-mail Address: malaekehb@mums.ac.ir

    Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, PO Box 91775-1365 Mashhad, Iran

    Search for more papers by this author

    Published Online:1 Sep 2016https://doi.org/10.4155/tde-2016-0045

    Abstract

    The most common method for cancer treatment is chemotherapy. Multidrug resistance (MDR) is one of the major obstacles in chemotherapeutic treatment of many human cancers. One strategy to overcome this challenge is the delivery of anticancer drugs and siRNA simultaneously using nanoparticles. Mesoporous silica nanoparticles are one of the most popular nanoparticles for cargo delivery because of their intrinsic porosity. This paper highlights recent advances in codelivery of chemotherapeutic and siRNA with mesoporous silica nanoparticles for cancer therapy. In addition, synthesis and functionalization approaches of these nanoparticles are summarized. This review presents insight into the utilization of nanoparticles and combination therapy to achieve more promising results in chemotherapy.

    References

    • 1 Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53(46), 12320–12364 (2014).Medline, CAS, Google Scholar
    • 2 Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 64(15), 1730–1737 (2012).Crossref, Medline, CAS, Google Scholar
    • 3 Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer. 11(1), 59–67 (2011).Crossref, Medline, CAS, Google Scholar
    • 4 Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 87, 108–119 (2015).Crossref, Medline, CAS, Google Scholar
    • 5 Tan SJ, Kiatwuthinon P, Roh YH, Kahn JS, Luo D. Engineering nanocarriers for siRNA delivery. Small 7(7), 841–856 (2011).Crossref, Medline, CAS, Google Scholar
    • 6 Ku SH, Kim K, Choi K, Kim SH, Kwon IC. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv. Healthc. Mater. 3(8), 1182–1193 (2014).Crossref, Medline, CAS, Google Scholar
    • 7 Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv. Drug. Deliv. Rev. 61(10), 850–862 (2009).Crossref, Medline, CAS, Google Scholar
    • 8 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007).Crossref, Medline, CAS, Google Scholar
    • 9 Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761–769 (2008).Crossref, Medline, CAS, Google Scholar
    • 10 Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Rel. 200, 138–157 (2015).Crossref, Medline, CAS, Google Scholar
    • 11 Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2–25 (2014).Crossref, Medline, CAS, Google Scholar
    • 12 Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136–151 (2011).Crossref, Medline, CAS, Google Scholar
    • 13 Nichols JW, Bae YH. EPR: evidence and fallacy. J. Control. Rel. 190, 451–464 (2014).Crossref, Medline, CAS, Google Scholar
    • 14 Wang X, Li S, Shi Y et al. The development of site-specific drug delivery nanocarriers based on receptor mediation. J. Control. Rel. 193, 139–153 (2014).Crossref, Medline, CAS, Google Scholar
    • 15 Arabi L, Badiee A, Mosaffa F, Jaafari MR. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. J. Control. Rel. 220(Part A), 275–286 (2015).Crossref, Medline, CAS, Google Scholar
    • 16 Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J. Pharm. Sci. 102(6), 1994–2004 (2013).Crossref, Medline, CAS, Google Scholar
    • 17 Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J. Drug. Target. 16(2), 108–123 (2008).Crossref, Medline, CAS, Google Scholar
    • 18 Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem. Soc. Rev. 41(7), 2740–2779 (2012).Crossref, Medline, CAS, Google Scholar
    • 19 Slowing Ii, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug. Deliv. Rev. 60(11), 1278–1288 (2008).Crossref, Medline, CAS, Google Scholar
    • 20 Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112(11), 5818–5878 (2012).Crossref, Medline, CAS, Google Scholar
    • 21 Aznar E, Oroval M, Pascual L, Murguía JR, Martínez-Máñez R, Sancenón F. Gated materials for on-command release of guest molecules. Chem. Rev. 116(2), 561–718 (2016).Crossref, Medline, CAS, Google Scholar
    • 22 He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 21(16), 5845–5855 (2011).Crossref, CAS, Google Scholar
    • 23 Giri S, Trewyn BG, Stellmaker MP, Lin VS. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew. Chem. Int. Ed. Engl. 44(32), 5038–5044 (2005).Crossref, Medline, CAS, Google Scholar
    • 24 Aznar E, Marcos MD, Martinez-Manez R et al. pH- and photo-switched release of guest molecules from mesoporous silica supports. J. Am. Chem. Soc. 131(19), 6833–6843 (2009).Crossref, Medline, CAS, Google Scholar
    • 25 Chen AM, Zhang M, Wei D et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5(23), 2673–2677 (2009).Crossref, Medline, CAS, Google Scholar
    • 26 Climent E, Bernardos A, Martinez-Manez R et al. Controlled delivery systems using antibody-capped mesoporous nanocontainers. J. Am. Chem. Soc. 131(39), 14075–14080 (2009).Crossref, Medline, CAS, Google Scholar
    • 27 Oroval M, Climent E, Coll C et al. An aptamer-gated silica mesoporous material for thrombin detection. J. Chem. Soc. Chem. Commun. 49(48), 5480–5482 (2013).Crossref, CAS, Google Scholar
    • 28 De La Torre C, Agostini A, Mondragón L et al. Temperature-controlled release by changes in the secondary structure of peptides anchored onto mesoporous silica supports. J. Chem. Soc. Chem. Commun. 50(24), 3184–3186 (2014).Crossref, CAS, Google Scholar
    • 29 Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359(6397), 710–712 (1992).Crossref, CAS, Google Scholar
    • 30 Vallet-Regi M, Rámila A, Del Real RP, Pérez-Pariente J. A new property of MCM-41:drug delivery system. Chem. Mater. 13(2), 308–311 (2001).Crossref, CAS, Google Scholar
    • 31 Wu S-H, Mou C-Y, Lin H-P. Synthesis of mesoporous silica nanoparticles. Chem. Soc. Rev. 42(9), 3862–3875 (2013).Crossref, Medline, CAS, Google Scholar
    • 32 Lin YS, Hurley KR, Haynes CL. Critical considerations in the biomedical use of mesoporous silica nanoparticles. J. Phys. Chem. Lett. 3(3), 364–374 (2012).Crossref, Medline, CAS, Google Scholar
    • 33 Hanafi-Bojd MY, Jaafari MR, Ramezanian N et al. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur. J. Pharm. Biopharm. 89(0), 248–258 (2015).Crossref, Medline, CAS, Google Scholar
    • 34 Urata C, Aoyama Y, Tonegawa A, Yamauchi Y, Kuroda K. Dialysis process for the removal of surfactants to form colloidal mesoporous silica nanoparticles. Chem. Commun. (Camb.) 34, 5094–5096 (2009).Crossref, Medline, Google Scholar
    • 35 Hoffmann F, Cornelius M, Morell J, Froba M. Silica-based mesoporous organic-inorganic hybrid materials. Angew. Chem. Int. Ed. Engl. 45(20), 3216–3251 (2006).Crossref, Medline, CAS, Google Scholar
    • 36 Wu S-H, Hung Y, Mou C-Y. Mesoporous silica nanoparticles as nanocarriers. Chem. Commun. 47(36), 9972–9985 (2011).Crossref, Medline, CAS, Google Scholar
    • 37 Sadeghnia HR, Zoljalali N, Hanafi-Bojd MY, Nikoofal-Sahlabadi S, Malaekeh-Nikouei B. Effect of mesoporous silica nanoparticles on cell viability and markers of oxidative stress. Toxicol. Mech. Methods. 25(6), 433–439 (2015).Medline, CAS, Google Scholar
    • 38 Meng H, Liong M, Xia T et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4(8), 4539–4550 (2010).Crossref, Medline, CAS, Google Scholar
    • 39 Li X, Xie QR, Zhang J, Xia W, Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 32(35), 9546–9556 (2011).Crossref, Medline, CAS, Google Scholar
    • 40 Radu DR, Lai CY, Jeftinija K, Rowe EW, Jeftinija S, Lin VS. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 126(41), 13216–13217 (2004).Crossref, Medline, CAS, Google Scholar
    • 41 Zhu Y, Meng W, Gao H, Hanagata N. Hollow mesoporous silica/poly(l-lysine) particles for codelivery of drug and gene with enzyme-triggered release property. J. Phys. Chem. C 115(28), 13630–13636 (2011).Crossref, CAS, Google Scholar
    • 42 Qin F, Zhou Y, Shi J, Zhang Y. A DNA transporter based on mesoporous silica nanospheres mediated with polycation poly(allylamine hydrochloride) coating on mesopore surface. J. Biomed. Mater. Res. A 90A(2), 333–338 (2009).Crossref, CAS, Google Scholar
    • 43 Ngamcherdtrakul W, Morry J, Gu S et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv. Funct. Mater. 25(18), 2646–2659 (2015).Crossref, Medline, CAS, Google Scholar
    • 44 Jabr-Milane LS, Van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer. Treat. Rev. 34(7), 592–602 (2008).Crossref, Medline, CAS, Google Scholar
    • 45 Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7(4), 367–379 (2012).Crossref, Medline, CAS, Google Scholar
    • 46 Meng H, Mai WX, Zhang H et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7(2), 994–1005 (2013).Crossref, Medline, CAS, Google Scholar
    • 47 Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Abnous K, Malaekeh-Nikouei B. Co-delivery of epirubicin and siRNA using functionalized mesoporous silica nanoparticles enhances in vitro and in vivo drug efficacy. Curr. Drug. Deliv. 13 (2016) (Epub ahead of print). doi:10.2174/1567201813666151231094056.Medline, Google Scholar
    • 48 Ma X, Teh C, Zhang Q et al. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery for siRNA and doxorubicin. Antioxid. Redox. Signal. 21(5), 707–722 (2013).Crossref, Medline, Google Scholar
    • 49 Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug. Target. 19(10), 900–914 (2011).Crossref, Medline, CAS, Google Scholar
    • 50 Ma X, Zhao Y, Ng KW, Zhao Y. Integrated hollow mesoporous silica nanoparticles. Chem-Eur. J. 19(46), 15593–15603 (2013).Crossref, Medline, CAS, Google Scholar
    • 51 Li T, Shen X, Geng Y et al. Folate-functionalized magnetic-mesoporous silica nanoparticles for drug/gene codelivery to potentiate the antitumor efficacy. ACS. Appl. Mater. Interfaces 8(22), 13748–13758 (2016).Crossref, Medline, CAS, Google Scholar
    • 52 Qi X, Yu D, Jia B et al. Targeting CD133+ laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles. Tumour Biol. 37(2), 2209–2217 (2016).Crossref, Medline, CAS, Google Scholar
    • 53 Han L, Tang C, Yin C. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. Biomaterials 60, 42–52 (2015).Crossref, Medline, CAS, Google Scholar